338 related articles for article (PubMed ID: 23625802)
1. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
2. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Joshi SS; Ortiz S; Witherspoon JN; Rademaker A; West DP; Anderson R; Rosenbaum SE; Lacouture ME
Cancer; 2010 Aug; 116(16):3916-23. PubMed ID: 20564072
[TBL] [Abstract][Full Text] [Related]
3. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
4. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
5. Pruritus Associated with Targeted Anticancer Therapies and Their Management.
Wu J; Lacouture ME
Dermatol Clin; 2018 Jul; 36(3):315-324. PubMed ID: 29929603
[TBL] [Abstract][Full Text] [Related]
6. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
7. Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4.
Fischer A; Rosen AC; Ensslin CJ; Wu S; Lacouture ME
Dermatol Ther; 2013; 26(2):135-48. PubMed ID: 23551370
[TBL] [Abstract][Full Text] [Related]
8. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Supportive Oncodermatology Interventions on Patient Quality of Life: A Cross-Sectional Survey.
Aizman L; Nelson K; Sparks AD; Friedman AJ
J Drugs Dermatol; 2020 May; 19(5):477-482. PubMed ID: 32484625
[TBL] [Abstract][Full Text] [Related]
10. Side effects of targeted therapies: rash.
Eaby-Sandy B; Lynch K
Semin Oncol Nurs; 2014 Aug; 30(3):147-54. PubMed ID: 25085026
[TBL] [Abstract][Full Text] [Related]
11. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients.
Ra HS; Shin SJ; Kim JH; Lim H; Cho BC; Roh MR
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e53-9. PubMed ID: 22329482
[TBL] [Abstract][Full Text] [Related]
12. [Adverse cutaneous effects and quality of life in patients treated with mTOR inhibitors for renal carcinoma].
Voilliot-Trotot C; Granel-Brocard F; Geoffrois L; Tréchot P; Nguyen-Thi P; Schmutz JL; Barbaud A
Ann Dermatol Venereol; 2013 May; 140(5):353-62. PubMed ID: 23663707
[TBL] [Abstract][Full Text] [Related]
13. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies.
Chan A; Cameron MC; Garden B; Boers-Doets CB; Schindler K; Epstein JB; Choi J; Beamer L; Roeland E; Russi EG; Bensadoun RJ; Teo YL; Chan RJ; Shih V; Bryce J; Raber-Durlacher J; Gerber PA; Freytes CO; Rapoport B; LeBoeuf N; Sibaud V; Lacouture ME
Support Care Cancer; 2015 Aug; 23(8):2231-44. PubMed ID: 25564221
[TBL] [Abstract][Full Text] [Related]
15. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
16. Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study.
Barrios DM; Phillips GS; Freites-Martinez A; Hsu M; Ciccolini K; Skripnik Lucas A; Marchetti MA; Rossi AM; Lee EH; Deng L; Markova A; Myskowski PL; Lacouture ME
J Eur Acad Dermatol Venereol; 2020 Jun; 34(6):1340-1347. PubMed ID: 31856311
[TBL] [Abstract][Full Text] [Related]
17. Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis.
Ensslin CJ; Rosen AC; Wu S; Lacouture ME
J Am Acad Dermatol; 2013 Nov; 69(5):708-720. PubMed ID: 23981682
[TBL] [Abstract][Full Text] [Related]
18. [Skin toxicities and unmet supportive care needs of patients with cancer undergoing EGFR-inhibitor therapy].
Matzka M; Stöhr D; Colditz A; Köck-Hódi S; Koller M; Mayer H
Pflege; 2017 Jan; 30(1):9-17. PubMed ID: 27901405
[TBL] [Abstract][Full Text] [Related]
19. Nasal vestibulitis due to targeted therapies in cancer patients.
Ruiz JN; Belum VR; Boers-Doets CB; Kamboj M; Babady NE; Tang YW; Valdez TA; Lacouture ME
Support Care Cancer; 2015 Aug; 23(8):2391-8. PubMed ID: 25876156
[TBL] [Abstract][Full Text] [Related]
20. Quality of life in patients with anogenital warts.
Paradisi A; Capizzi R; Ricci F; Di Pietro C; Abeni D; Tabolli S
Eur J Dermatol; 2013; 23(6):837-42. PubMed ID: 24192222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
